The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly.

PURPOSE The North Central Cancer Treatment Group performed a phase III trial to determine whether chemotherapy plus either bid radiation therapy (RT) or daily (qd) RT resulted in a better outcome for patients with stage III non-small-cell lung cancer (NSCLC). No difference in survival was identified between the two arms. This secondary analysis was performed to examine the relationship between patient age and outcome. PATIENTS AND METHODS Two hundred forty-six patients were randomized to receive etoposide plus cisplatin and either RT qd or split-course RT bid. This retrospective study compared the outcomes of patients aged >/=70 years ("elderly patients") with those of younger individuals. Of the 244 assessable patients, 63 (26%) were elderly, and 181 (74%) were younger individuals. RESULTS The 2-year and 5-year survival rates were 39% and 18%, respectively, in patients younger than 70 years, compared with 36% and 13%, respectively, in elderly patients (P =.4). Grade 4+ toxicity occurred in 62% of patients younger than 70 years compared with 81% of elderly patients (P =.007). Grade 4+ hematologic toxicity occurred in 56% of patients younger than 70 years, compared with 78% of elderly patients (P =.003). Grade 4+ pneumonitis occurred in 1% of those younger than 70 years, compared with 6% of elderly patients (P =.02). CONCLUSION Toxicity, especially myelosuppression and pneumonitis, was more pronounced in the elderly patients receiving combined-modality therapy for locally advanced NSCLC. Despite increased toxicity, elderly patients have survival rates equivalent to younger individuals. Therefore, fit, elderly patients with locally advanced NSCLC should be encouraged to receive combined-modality therapy, preferably on clinical trials with cautious, judicious monitoring. Future studies should explore ways to decrease toxicity of therapy in elderly patients.

[1]  E. Perez,et al.  Weekly Carboplatin and Paclitaxel in Elderly Non–Small-Cell Lung Cancer Patients (≥65 Years of Age): A Phase II North Central Cancer Treatment Group Study , 2003, American journal of clinical oncology.

[2]  J. Jett,et al.  Phase III trial comparing chemotherapy plus once-daily or twice-daily radiotherapy in Stage III non-small-cell lung cancer. , 2002, International journal of radiation oncology, biology, physics.

[3]  W. Curran,et al.  Do elderly patients (pts) with locally advanced non-small cell lung cancer (NSCLC) benefit from combined modality therapy? a secondary analysis of RTOG 94-10 , 2001 .

[4]  L. Tripcony,et al.  The curative treatment by radiation therapy alone of Stage I non-small cell lung cancer in a geriatric population. , 2001, Lung cancer.

[5]  W. Curran,et al.  Effect of advanced age on outcome in Radiation Therapy Oncology Group studies of locally advanced NSCLC (LA-NSCLC) , 2000 .

[6]  S. Kudoh,et al.  Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  K. Ang,et al.  Altered fractionation trials in head and neck cancer. , 1998, Seminars in radiation oncology.

[8]  W. Curran,et al.  Induction cisplatin/vinblastine and irradiation vs. irradiation in unresectable squamous cell lung cancer: failure patterns by cell type in RTOG 88-08/ECOG 4588. Radiation Therapy Oncology Group. Eastern Cooperative Oncology Group. , 1997, International journal of radiation oncology, biology, physics.

[9]  J. Herndon,et al.  Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. , 1996, Journal of the National Cancer Institute.

[10]  C. C. Wang.  Altered fractionated radiation therapy for head and neck carcinomas--A Massachusetts General Hospital experience. , 1996, Annals of the Academy of Medicine, Singapore.

[11]  O. Brodin,et al.  Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials , 1995 .

[12]  R. Arriagada,et al.  Radiotherapy alone versus combined chemotherapy and radiotherapy in unresectable non-small cell lung carcinoma. , 1994, Lung cancer.

[13]  E. Shaw,et al.  Pilot study of accelerated hyperfractionated thoracic radiation therapy plus concomitant etoposide and cisplatin chemotherapy in patients with unresectable stage III non-small-cell carcinoma of the lung. , 1993, Journal of the National Cancer Institute.

[14]  E. Noordijk,et al.  Radiotherapy as an alternative to surgery in elderly patients with resectable lung cancer. , 1988, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[15]  M. Pike,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.

[16]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[17]  Ahmedin Jemal,et al.  Cancer Statistics, 2002 , 2002, CA: a cancer journal for clinicians.

[18]  J. Herndon,et al.  Therapy choices among older patients with lung carcinoma , 2002, Cancer.

[19]  W. Curran,et al.  Sequential vs. concurrent chemotherapy and radiation therapy for inoperable non-small cell lung cancer (NSCLC): Analysis of failures in a phase III study (RTOG 9410) , 2000 .

[20]  Jay S. Cooper,et al.  A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003 , 1999 .

[21]  W. Mendenhall,et al.  Altered fractionation in radiation therapy for squamous-cell carcinoma of the head and neck. , 1998, Cancer investigation.